 |
PDBsum entry 1ror
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structures of the catalytic domain of phosphodiesterase 4b2b complexed with amp
|
|
Structure:
|
 |
Camp-specific 3',5'-cyclic phosphodiesterase 4b. Chain: a, b. Fragment: catalytic domain. Synonym: dpde4, pde32. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pde4b. Expressed in: unidentified baculovirus. Expression_system_taxid: 10469
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.209
|
R-free:
|
0.228
|
|
|
Authors:
|
 |
R.X.Xu,W.J.Rocque,M.H.Lambert,D.E.Vanderwall,R.T.Nolte
|
Key ref:
|
 |
R.X.Xu
et al.
(2004).
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
J Mol Biol,
337,
355-365.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
02-Dec-03
|
Release date:
|
07-Dec-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q07343
(PDE4B_HUMAN) -
cAMP-specific 3',5'-cyclic phosphodiesterase 4B from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
736 a.a.
338 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 2 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.4.53
- 3',5'-cyclic-AMP phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
3',5'-cyclic AMP + H2O = AMP + H+
|
 |
 |
 |
 |
 |
3',5'-cyclic AMP
|
+
|
H2O
|
=
|
AMP
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Mol Biol
337:355-365
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
|
|
R.X.Xu,
W.J.Rocque,
M.H.Lambert,
D.E.Vanderwall,
M.A.Luther,
R.T.Nolte.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Phosphodiesterase catalyzes the hydrolysis of the intracellular second messenger
3',5'-cyclic AMP (cAMP) into the corresponding 5'-nucleotide. Phosphodiesterase
4 (PDE4), the major cAMP-specific PDE in inflammatory and immune cells, is an
attractive target for the treatment of asthma and COPD. We have determined
crystal structures of the catalytic domain of PDE4B complexed with AMP (2.0 A),
8-Br-AMP (2.13 A) and the potent inhibitor rolipram (2.0 A). All the ligands
bind in the same hydrophobic pocket and can interact directly with the active
site metal ions. The identity of these metal ions was examined using X-ray
anomalous difference data. The structure of the AMP complex confirms the
location of the catalytic site and allowed us to speculate about the detailed
mechanism of catalysis. The high-resolution structures provided the experimental
insight into the nucleotide selectivity of phosphodiesterase. 8-Br-AMP binds in
the syn conformation to the enzyme and demonstrates an alternative
nucleotide-binding mode. Rolipram occupies much of the AMP-binding site and
forms two hydrogen bonds with Gln443 similar to the nucleotides.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 7.
Figure 7. Binding of 8-Br-AMP in the PDE4B active site. The
protein backbone is shown as a gray ribbon. The Br is colored
dark red. The carbon atoms of 8-Br-AMP are colored yellow, the
phosphate is colored pink. The carbon atoms of important
side-chain of the protein are shown in green. The metal ions are
shown as yellow balls. The hydrogen bonds between protein and
8-Br-AMP are shown as white dotted lines. The protein
interactions with metal ions are shown as cyan dotted lines.
|
 |
Figure 8.
Figure 8. Comparison of the AMP and 8-Br-AMP bound to
PDE4B. Schematic representation of the ligand-binding mode for
each molecule including the major hydrogen bond interactions
seen between each ligand and the active site.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2004,
337,
355-365)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.K.Malde,
and
A.E.Mark
(2011).
Challenges in the determination of the binding modes of non-standard ligands in X-ray crystal complexes.
|
| |
J Comput Aided Mol Des,
25,
1.
|
 |
|
|
|
|
 |
A.B.Burgin,
O.T.Magnusson,
J.Singh,
P.Witte,
B.L.Staker,
J.M.Bjornsson,
M.Thorsteinsdottir,
S.Hrafnsdottir,
T.Hagen,
A.S.Kiselyov,
L.J.Stewart,
and
M.E.Gurney
(2010).
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
|
| |
Nat Biotechnol,
28,
63-70.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.J.Hill,
C.Williams,
and
L.T.May
(2010).
Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.
|
| |
Br J Pharmacol,
161,
1266-1275.
|
 |
|
|
|
|
 |
A.P.Skoumbourdis,
C.A.Leclair,
E.Stefan,
A.G.Turjanski,
W.Maguire,
S.A.Titus,
R.Huang,
D.S.Auld,
J.Inglese,
C.P.Austin,
S.W.Michnick,
M.Xia,
and
C.J.Thomas
(2009).
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
|
| |
Bioorg Med Chem Lett,
19,
3686-3692.
|
 |
|
|
|
|
 |
J.L.Weeks,
J.D.Corbin,
and
S.H.Francis
(2009).
Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
|
| |
J Pharmacol Exp Ther,
331,
133-141.
|
 |
|
|
|
|
 |
J.Pandit,
M.D.Forman,
K.F.Fennell,
K.S.Dillman,
and
F.S.Menniti
(2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
|
| |
Proc Natl Acad Sci U S A,
106,
18225-18230.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.T.Aye,
S.Mohammed,
H.W.van den Toorn,
T.A.van Veen,
M.A.van der Heyden,
A.Scholten,
and
A.J.Heck
(2009).
Selectivity in enrichment of cAMP-dependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins.
|
| |
Mol Cell Proteomics,
8,
1016-1028.
|
 |
|
|
|
|
 |
G.G.Holz,
O.G.Chepurny,
and
F.Schwede
(2008).
Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors.
|
| |
Cell Signal,
20,
10-20.
|
 |
|
|
|
|
 |
M.D.Zimmerman,
M.Proudfoot,
A.Yakunin,
and
W.Minor
(2008).
Structural insight into the mechanism of substrate specificity and catalytic activity of an HD-domain phosphohydrolase: the 5'-deoxyribonucleotidase YfbR from Escherichia coli.
|
| |
J Mol Biol,
378,
215-226.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Liu,
M.N.Mansour,
K.S.Dillman,
J.R.Perez,
D.E.Danley,
P.A.Aeed,
S.P.Simons,
P.K.Lemotte,
and
F.S.Menniti
(2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
|
| |
Proc Natl Acad Sci U S A,
105,
13309-13314.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Wang,
H.Robinson,
and
H.Ke
(2007).
The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10.
|
| |
J Mol Biol,
371,
302-307.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Wang,
Y.Liu,
J.Hou,
M.Zheng,
H.Robinson,
and
H.Ke
(2007).
Structural insight into substrate specificity of phosphodiesterase 10.
|
| |
Proc Natl Acad Sci U S A,
104,
5782-5787.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Johner,
S.Kunz,
M.Linder,
Y.Shakur,
and
T.Seebeck
(2006).
Cyclic nucleotide specific phosphodiesterases of Leishmania major.
|
| |
BMC Microbiol,
6,
25.
|
 |
|
|
|
|
 |
C.Lugnier
(2006).
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
|
| |
Pharmacol Ther,
109,
366-398.
|
 |
|
|
|
|
 |
F.G.Oliveira,
C.M.Sant'Anna,
E.R.Caffarena,
L.E.Dardenne,
and
E.J.Barreiro
(2006).
Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors.
|
| |
Bioorg Med Chem,
14,
6001-6011.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Q.Huai,
J.Cai,
R.Zoraghi,
S.H.Francis,
J.D.Corbin,
H.Robinson,
Z.Xin,
G.Lin,
and
H.Ke
(2006).
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
|
| |
J Biol Chem,
281,
21469-21479.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Montalibet,
K.Skorey,
D.McKay,
G.Scapin,
E.Asante-Appiah,
and
B.P.Kennedy
(2006).
Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding.
|
| |
J Biol Chem,
281,
5258-5266.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Q.Huai,
Y.Sun,
H.Wang,
D.Macdonald,
R.Aspiotis,
H.Robinson,
Z.Huang,
and
H.Ke
(2006).
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
|
| |
J Med Chem,
49,
1867-1873.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Zoraghi,
J.D.Corbin,
and
S.H.Francis
(2006).
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
|
| |
J Biol Chem,
281,
5553-5558.
|
 |
|
|
|
|
 |
A.Castro,
M.J.Jerez,
C.Gil,
and
A.Martinez
(2005).
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
|
| |
Med Res Rev,
25,
229-244.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Y.Chen,
H.Robinson,
and
H.Ke
(2005).
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
|
| |
J Biol Chem,
280,
30949-30955.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
P.N.Ibrahim,
S.Gillette,
and
G.Bollag
(2005).
Phosphodiesterase-4 as a potential drug target.
|
| |
Expert Opin Ther Targets,
9,
1283-1305.
|
 |
|
|
|
|
 |
M.D.Houslay,
P.Schafer,
and
K.Y.Zhang
(2005).
Keynote review: phosphodiesterase-4 as a therapeutic target.
|
| |
Drug Discov Today,
10,
1503-1519.
|
 |
|
|
|
|
 |
S.Kunz,
M.Oberholzer,
and
T.Seebeck
(2005).
A FYVE-containing unusual cyclic nucleotide phosphodiesterase from Trypanosoma cruzi.
|
| |
FEBS J,
272,
6412-6422.
|
 |
|
|
|
|
 |
G.L.Card,
B.P.England,
Y.Suzuki,
D.Fong,
B.Powell,
B.Lee,
C.Luu,
M.Tabrizizad,
S.Gillette,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2004).
Structural basis for the activity of drugs that inhibit phosphodiesterases.
|
| |
Structure,
12,
2233-2247.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
G.L.Card,
Y.Suzuki,
D.R.Artis,
D.Fong,
S.Gillette,
D.Hsieh,
J.Neiman,
B.L.West,
C.Zhang,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
G.Bollag
(2004).
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
|
| |
Mol Cell,
15,
279-286.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Conti
(2004).
A view into the catalytic pocket of cyclic nucleotide phosphodiesterases.
|
| |
Nat Struct Mol Biol,
11,
809-810.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |